Epidemiological and clinicopathological characteristics of eCPMV-treated and control canine IMC patients
| Patient | Age, y. | Weight, kg | TS,* cm | TS,† cm3 | Breed | Type | Histo. grade | Histo. type | sdLVI | LNI | Therapy | OS, days |
| eCPMV-treated IMC patients | ||||||||||||
| P1 | 11.0 | 10.3 | 15.1 | 74.8 | Mixed | Primary | III | Special type | Yes | Yes | +FCT | 174 |
| P2 | 13.5 | 25.6 | 15.7 | 45.7 | Mixed | Secondary | III | Simple | Yes | Yes | +FCT | 156 |
| P3 | 10.7 | 8.2 | 19.6 | 104.2 | Poodle | Secondary | III | Simple | Yes | Yes | +FCT | 109 |
| P4 | 10.7 | 17.0 | 17.3 | 52.7 | Kerry Blue Terrier | Secondary | III | Simple | Yes | Yes | +FCT | 165 |
| P5 | 11.9 | 2.7 | 3.9 | 4.3 | Bichon Frise | Secondary | III | Simple | Yes | Yes | +FCT | 67 |
| Control IMC patients | ||||||||||||
| P6 | 13.0 | 26.2 | 14.0 | 252.0 | Mixed | Secondary | III | DA | Yes | Yes | FCT | 27 |
| P7 | 14.2 | 7.6 | 7.0 | 14.0 | Maltese | Secondary | III | Simple | Yes | Yes | FCT | 40 |
| P8 | 9.7 | 10.3 | 4.0 | 32.0 | Mixed | Secondary | III | Simple | Yes | Yes | FCT | 132 |
| P9 | 13.0 | 9.3 | 5.0 | 30.6 | Miniature Schnauzer | Secondary | III | Simple | Yes | Yes | FCT | 63 |
| P10 | 8.9 | 7.7 | 3.0 | 9.4 | Poodle | Secondary | III | Simple | Yes | Yes | FCT | 73 |
Age at diagnosis in years.
+FCT indicates that eCPMV-treated dogs received FCT therapy starting after second eCPMV injection until surgery or death, and P1 and P5 continued on FCT as adjuvant therapy until death.
*TS refers to the largest diameter of the target tumor in cm.
†TS refers to tumor volume in cm3; type, refers to primary and secondary IMC.
DA, ductal associated; eCPMV, empty cowpea mosaic virus; FCT, firocoxib+cyclophosphamide+toceranib; Histo, histologic; IMC, inflammatory mammary cancer; LNI, regional lymph node involvement; OS, overall survival time; sdLVI, superficial dermal lymphovascular invasion; TS, tumor size.